Dr. Reddy's Laboratories Limited (NYSE:RDY) Stock Position Lifted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 405.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,361,013 shares of the company's stock after buying an additional 4,301,212 shares during the quarter. Dimensional Fund Advisors LP owned 0.64% of Dr. Reddy's Laboratories worth $84,643,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AIA Group Ltd increased its stake in Dr. Reddy's Laboratories by 441.7% during the fourth quarter. AIA Group Ltd now owns 145,150 shares of the company's stock valued at $2,292,000 after purchasing an additional 118,357 shares during the last quarter. Vanguard Group Inc. grew its stake in Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after buying an additional 3,911,404 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after buying an additional 9,373,412 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of Dr. Reddy's Laboratories by 609.4% during the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after acquiring an additional 5,015 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Dr. Reddy's Laboratories by 400.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock worth $8,373,000 after acquiring an additional 427,573 shares during the last quarter. Institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

NYSE:RDY traded down $0.15 during mid-day trading on Monday, hitting $13.86. The stock had a trading volume of 131,636 shares, compared to its average volume of 1,471,954. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $13.23 and a 200-day simple moving average of $14.14. The stock has a market capitalization of $11.57 billion, a price-to-earnings ratio of 22.06 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.